Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb reports second quarter sales growth

Bristol-Myers Squibb reports second quarter sales growth

23rd July 2010

Bristol-Myers Squibb has published its financial results for the second quarter of 2010, reporting a two per cent year-on-year sales increase.

The biopharmaceutical firm’s net sales total rose to $4.8 billion (3.1 billion pounds), a growth which was primarily attributed to the firm’s virology treatment franchise.

Drugs such as Baraclude, Reyataz, Sustiva and Orencia were all named among the products which saw sales improvements in Q2 2010 compared to the same period a year earlier.

The report also highlighted the filing of applications for regulatory approval of drugs such as Sprycel and ipilimumab, as well as the success of the firm’s share repurchase programme.

Lamberto Andreotti, chief executive officer at Bristol-Myers Squibb, said: “Our second quarter performance continues to strengthen our confidence in our ability to execute the key elements of our differentiated and focused biopharma strategy.”

Earlier this month, the company was granted European regulatory approval for a new indication of its HIV drug Reyataz to be used among paediatric patients.ADNFCR-8000103-ID-800004420-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.